Little Green Pharma has been selected to supply the French medical cannabis pilot program TSX Venture Exchange: ELXR


MONTRÉAL, January 27, 2021 (GLOBE NEWSWIRE) – Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“Elixxer” or the “Company”) is pleased to announce the latest achievements of its largest holding Little Green Pharma Ltd. (LGP). LGP has reached the following important milestone that confirms our investment:

The French Agency for the Safety of Medicines and Health Products (ANSM) has selected Little Green Pharma as one of four companies to supply the French medical cannabis pilot program. As part of the program, participants will receive free products for patients participating in the study. LGP will be both the main and replacement supplier of sublingual CBD oils.

Elixxer currently holds 27.4 million LGP shares and on January 27, 2021, the closing price was $ 0.64 per share on the ASX. Click the link: LGP share price

Elixxer will keep investors up to date on further developments from its holdings by means of a press release.

About Elixxer Ltd. (

Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC QB exchange (OTCQB: ELIXF).

Elixxer currently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada through its partners.

For more information, please contact:

Be careful with press releases

Neither the TSX Venture Exchange nor its regulatory services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary note regarding forward-looking statements

This press release may contain forward-looking statements regarding Elixxer and its business, strategy, investments, financial performance and situation. These statements can generally be identified by the use of forward-looking words such as “may,” “will,” “expect,” “estimate,” “anticipate,” “intend,” “believe” or “continue” or the negatives of these or similar variations . Actual results and performance of Elixxer could differ materially from those expressed or implied in these statements. Such statements are qualified in their entirety by the inherent risks and uncertainties associated with future expectations. Some important factors that could cause actual results to differ materially from expectations include, but are not limited to, general economic and market factors, competition, government regulation, and the factors identified under “Risk Factors and Risk Management” in the most recent discussion and analysis of the management of Elixxer are described on SEDAR ( The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and Elixxer undertakes no obligation to update these statements unless required by applicable securities laws.